|

ASTX727 Clinical Trials

9 actively recruiting trials across 4 locations

Also known as: C-DEC, INQOVI, Inqovi, Oral decitabine and cedazuridine

Houston, Texas4 trials

A Phase I-II Study Investigating the All-Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)

M D Anderson Cancer Center

Phase 1/2
A Phase Ia/Ib Open-label, Multiple Dose, Study to Determine the Recommended Dose, Evaluate PKs, PDs, Safety, and Activity of Venetoclax in Combination With Oral Decitabine/Cedazuridine (ASTX727) in Pediatric Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)

MD Anderson Cancer Center

Phase 1
Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment

MD Anderson

Phase 1
Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment

MD Anderson

Phase 1

Other2 trials

Combination Study of Guadecitabine/ASTX727 and Pembrolizumab
Phase 1
Lutathera and ASTX727 in Neuroendocrine Tumours
Phase 1

San Francisco, California1 trial

Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors

University of California, San Francisco

Phase 1

Boston, Massachusetts1 trial

ASTX727 in Recurrent/Progressive Non-enhancing IDH Mutant Gliomas

Massachusetts General Hospital Cancer Center

Phase 1

Basking Ridge, New Jersey1 trial

A Study of ASTX727 in People With Malignant Peripheral Nerve Sheath Tumors (MPNST)

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.